Back to Search
Start Over
Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
- Source :
-
Critical care medicine [Crit Care Med] 2003 Jan; Vol. 31 (1), pp. 308-9. - Publication Year :
- 2003
- Subjects :
- Adult
Aged
Aged, 80 and over
Anti-Infective Agents therapeutic use
Cost-Benefit Analysis
Humans
Middle Aged
Protein C therapeutic use
Recombinant Proteins therapeutic use
Sepsis mortality
Survival Analysis
United States
Anti-Infective Agents economics
Health Care Costs
Protein C economics
Recombinant Proteins economics
Sepsis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0090-3493
- Volume :
- 31
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Critical care medicine
- Publication Type :
- Editorial & Opinion
- Accession number :
- 12545035
- Full Text :
- https://doi.org/10.1097/00003246-200301000-00050